Exhibit 99.1

DuPont Reports 4Q and Full-Year 2012 EPS of $.11 and $3.33 Ex-items

Expects Modest Growth in 2013 Operating Earnings

Fourth Quarter:

·                  Fourth quarter 2012 earnings per share (EPS) from continuing operations, excluding significant items, was $.11 versus prior year earnings of $.26.  Reported fourth quarter 2012 EPS from continuing operations was $.02 versus $.31 in the prior year.

·                  Sales of $7.3 billion equaled the prior year.  Three percent higher volume was offset by 2 percent negative currency impact and a 1 percent reduction from portfolio changes.

·                  Segment pre-tax operating income (PTOI) was down, primarily reflecting lower price and volume in Performance Chemicals.  Titanium dioxide pricing led the decline.

Full Year:

·                  2012 EPS from continuing operations, excluding significant items, was $3.33 versus $3.55 in 2011.  Currency was a $.27 per share headwind for the year.  Reported EPS from continuing operations was $2.61 versus $3.30 in 2011 (see Schedule B.)

·                  Sales were $34.8 billion, up 3 percent with a 6 percent increase in developing markets.

·                  Segment PTOI increased 3 percent to $5.7 billion, excluding Pharmaceuticals and significant items.  Agriculture PTOI increased 18 percent driven by volume and pricing growth for seed and crop protection businesses in North America and Latin America.  Performance Chemicals PTOI decreased 16 percent from lower sales across the segment.

·                  Free cash flow was $3.1 billion versus $3.3 billion in the prior year.  2012 includes a $0.5 billion contribution to the principal U.S. pension plan and lower net income, partly offset by improved working capital productivity.

·                  Fixed cost and working capital productivity benefits were each about $400 million, surpassing their $300 million targets.

·                  Reflecting the change in reporting for the cost of non-operating pension and other post-employment benefits and excluding significant items, 2012 operating earnings were $3.77 per share.  On the same basis, the 2013 outlook for operating earnings is $3.85 to $4.05 per share, an increase of 2 to 7 percent over the prior year.

“DuPont stands stronger today than it did a year ago.  Our segments delivered innovation, productivity and integration cost synergies.  This, coupled with a record year in new product introductions, has strengthened our market position,” said DuPont Chair and CEO Ellen Kullman.  “However, weakness in markets served by Performance Chemicals and Electronics & Communications provided significant challenges in 2012.  We’ve adjusted our plans to meet the changing market environment and grow our businesses in a slow-growth world economy.”

Global Consolidated Sales - 4th Quarter

Fourth quarter 2012 sales were $7.3 billion, flat versus the prior year.  Currency impact and portfolio changes offset 3 percent volume growth.  Volume was driven by Agriculture, with robust sales in Latin America and a strong start to the North American selling season, and increases in Asia Pacific for Performance Materials, Electronics & Communications and Performance Chemicals.  The table below shows fourth quarter regional sales and variances versus fourth quarter 2011.

Global Consolidated Sales - Full-Year

Full-year 2012 sales were $34.8 billion, up 3 percent versus 2011, reflecting 4 percent higher local prices, 2 percent adverse currency impact, 2 percent lower volume, and a 3 percent net increase from portfolio changes.  Local prices increased for all segments except Electronics & Communications which had lower pass-through of metals prices.  Lower global volume principally reflects decreases for Performance Chemicals and Electronics & Communications, partly offset by higher Agriculture volumes.  The table below shows regional sales and variances versus 2011.

* Europe, Middle East & Africa

2

Income from Continuing Operations - 4th Quarter

Excluding significant items, fourth quarter 2012 income from continuing operations was $110 million versus $246 million in the prior year.  The decrease principally reflects lower income from Performance Chemicals and Pharmaceuticals, increased spending for growth initiatives and adverse currency impact.  Reported fourth quarter 2012 income from continuing operations was $19 million versus $293 million in the fourth quarter 2011.

Earnings Per Share - 4th Quarter

The table below shows year-over-year earnings per share (EPS) variances for the fourth quarter.

EPS ANALYSIS

*                       Excludes volume and currency impacts

**                Includes interest expense, net exchange gains/losses, and other income

3

Business Segment Performance - 4th Quarter

The tables below show fourth quarter 2012 segment sales with related variances versus the prior year and fourth quarter PTOI excluding significant items.

SEGMENT SALES*

* Segment sales include transfers

SEGMENT PTOI excluding Significant Items*

* See Schedules B and C for listing of significant items and their impact by segment.

4

Business Segment Performance - Full Year

The tables below show full-year 2012 segment sales with related variances versus the prior year, and full-year PTOI excluding significant items.

SEGMENT SALES*

*                 Segment sales include transfers

SEGMENT PTOI excluding Significant Items*

* See Schedules B and C for listing of significant items and their impact by segment.

5

 The following is a summary of business results for each of the company’s reportable segments in the fourth quarter (unless otherwise noted), comparing current period with the prior year, for sales and PTOI (loss) excluding significant items.  References to selling price are on a U.S. dollar basis, including the impact of currency.

Agriculture — Sales of $1.5 billion were up 18 percent on 11 percent higher volume and 7 percent higher prices despite the negative impact of currency.  PTOI seasonal loss of ($92) million improved $24 million on higher volume in Latin America and stronger than expected pricing gains, partially offset by continued investment in commercial and R&D activities.

Full-year sales of $10.4 billion grew 14 percent on 8 percent higher volume and 6 percent higher prices.  Pioneer seed sales increased from higher global volume and pricing gains in corn and soybeans.  Crop Protection sales grew on strong demand for insecticides and herbicides in all regions.  Full-year PTOI increased 18 percent as strong sales more than offset unfavorable currency and higher investments in commercial and R&D activities to support growth.

Electronics & Communications — Sales of $622 million were down 1 percent, with 2 percent higher volume offset by 3 percent lower prices, primarily pass-through of lower metals prices.  Volume growth from increased demand for materials in smart phones and tablets was partly offset by continued softness in photovoltaic materials.  PTOI declined $18 million as the prior year included OLED technology licensing income of $20 million.

Industrial Biosciences — Sales of $300 million were up 4 percent on 3 percent higher volume and 1 percent higher prices.  Volume growth reflects strong sales of Sorona® polymer for carpeting, and continued growth in food enzymes in Europe.  PTOI of $44 million was up $10 million on higher volume and the benefit of synergies realized from the integration of the Danisco enzyme business.

Nutrition & Health — Sales of $853 million were up 6 percent on 3 percent higher volume and 3 percent higher prices.  Volume growth reflects strong demand for probiotics, cultures and enablers.  Higher local prices in all regions were partly offset by unfavorable currency.  PTOI of $66 million was up $14 million on higher sales and the benefit of synergies realized from the integration of the Danisco specialty food ingredients business, partly offset by higher raw material costs.

Performance Chemicals — Sales of $1.6 billion were down 15 percent, with 8 percent lower volume and 7 percent lower prices.  Lower volume resulted primarily from weak demand for fluoropolymers in U.S. and Europe.  Lower prices reflect cyclical pressure in the titanium dioxide market.  PTOI of $200 million decreased $233 million on lower sales and plant utilization in both businesses.

Performance Materials — Sales of $1.5 billion were down 5 percent, with 5 percent lower prices and a 3 percent reduction from a portfolio change, partly offset by 3 percent higher volume.  Stable packaging markets and strong demand in the North American automotive market were partially offset by softness in the industrial and electronics markets and a weak Europe.  PTOI of $254 million increased $103 million due to lower feedstock costs, higher volume and mix enrichment, partly offset by unfavorable currency.

Safety & Protection — Sales of $964 million were up 2 percent on 3 percent higher volume, partly offset by 1 percent lower prices due to unfavorable currency.  Volume increased on higher demand for Sustainable Solutions offerings and U.S. residential and commercial construction products.  PTOI of $88 million decreased $6 million primarily due to lower plant utilization related to softness in certain industrial markets and U.S. public sector markets.

Additional information is available on the DuPont Investor Center website at http://www.investors.dupont.com.

6

Outlook

Reflecting the change in reporting for the cost of non-operating pension and other post-employment benefits and excluding significant items, 2012 operating earnings were $3.77 per share.  On the same basis, the 2013 outlook for operating earnings is $3.85 to $4.05 per share, an increase of 2 to 7 percent over the prior year. First half 2013 operating earnings are expected to decline modestly on a year-over-year basis.  Additionally, full-year 2013 sales are expected to be about $36 billion.

Use of Non-GAAP Measures

Management believes that certain non-GAAP measurements are meaningful to investors because they provide insight with respect to ongoing operating results of the company.  Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance.  Reconciliations of non-GAAP measures to GAAP are provided in schedules C and D.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802.  The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.  For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates” or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company’s growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control.  Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; inability to protect and enforce the company’s intellectual property rights; and integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.  The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

#   #   #

7

E. I. du Pont de Nemours and Company

Consolidated Income Statements

(Dollars in millions, except per share amounts)

SCHEDULE A

(a) See Schedule B for detail of significant items.

(b) The sum of the individual earnings per share amounts may not equal the total due to rounding.

8

E. I. du Pont de Nemours and Company

Condensed Consolidated Balance Sheets

(Dollars in millions, except per share amounts)

SCHEDULE A (continued)

9

E. I. du Pont de Nemours and Company

Condensed Consolidated Statement of Cash Flows

(Dollars in millions)

SCHEDULE A (continued)

10

E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)

SCHEDULE B

SIGNIFICANT ITEMS FROM CONTINUING OPERATIONS

11

E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)

SCHEDULE B (continued)

SIGNIFICANT ITEMS FROM CONTINUING OPERATIONS

(a)         Fourth quarter 2012, third quarter 2012, second quarter 2012, first quarter 2012, fourth quarter 2011, and third quarter 2011 included charges of $(135), $(125), $(265), $(50), $(100), and $(75), respectively, recorded in Cost of goods sold and other operating charges associated with the company’s process to fairly resolve claims related to the use of Imprelis® herbicide, bringing the total charges to $(750) at December 31, 2012.  The company will continue to evaluate reported claim damage as additional information becomes available. It is reasonably possible that additional charges could result from this evaluation. While there is a high degree of uncertainty, total charges could range as high as $(900). The company has an applicable insurance program with a deductible equal to the first $100 of costs and expenses. The insurance program limits are $725 for costs and expenses in excess of the $100. The company has submitted, and will continue to submit, requests for payment to its insurance carriers for costs associated with this matter.  This matter relates to the Agriculture segment.

(b)         Second quarter 2012 included a charge of $(137) recorded in Cost of goods sold and other operating charges primarily related to the company’s settlement of litigation with Invista.  This matter is included in Other.

(c)          Second quarter 2012 included a pre-tax gain of $122 recorded in Other income, net associated with the sale of an equity method investment in the Electronics & Communications segment.

(d)         Second quarter 2011 included charges related to the Danisco acquisition of $(103) recorded in Cost of goods sold and other operating charges.  These charges included $(60) of transaction costs and a $(43) charge related to the fair value step-up of inventories that were acquired from Danisco and sold in the second quarter 2011. Pre-tax charges by segment were: Industrial Biosciences - $(17), Nutrition & Health - $(33), and Corporate expenses - $(53).

(e)          Third quarter 2012 included a $(152) restructuring charge recorded in Employee separation/asset related charges, net consisting of $(133) of severance and related benefit costs and $(19) of asset related charges as a result of the company’s plan to eliminate corporate costs previously allocated to Performance Coatings and cost-cutting actions to improve competitiveness.  Pre-tax charges by segment were: Agriculture - $(3), Nutrition & Health - $(13), Electronics & Communications - $(7), Performance Chemicals - $(3), Performance Materials - $(9), Safety & Protection - $(55), Industrial Biosciences - $(3), and Corporate expenses - $(59).

(f)           Third quarter 2012 included a $(242) impairment charge recorded in Employee separation/asset related charges, net related to asset groupings within the Electronics & Communications and Performance Materials segments. The charge of $(150) within Electronics & Communications was a result of conditions within the thin film photovoltaic market. The charge of $(92) within Performance Materials was the result of deteriorating conditions in an industrial polymer market.

(g)          Third quarter 2011 included charges related to the Danisco acquisition of $(171).  These charges included $(135) recorded in Cost of goods sold and other operating charges for $(3) of transaction costs and a $(132) charge related to the fair value step-up of inventories that were acquired from Danisco and sold in the third quarter 2011.  These charges also included a $(36) restructuring charge recorded in Employee separation / asset related charges, net related to severance and related benefit costs.  Pre-tax charges by segment were: Industrial Biosciences - $(61), Nutrition & Health - $(89), Other - $(18), and Corporate expenses - $(3).